Treatment for HIV infection and used as part of a 3-drug combination regimen.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT,AST, and total bilirubin.
Monitor fasting blood glucose or HbA1c at baseline and with modification of ARV treatment.
Common
Serious
Antimicrobial class: Antiretroviral agent, Integrase Inhibitor
Pregnancy category: C
Average serum half life: 9 hours
Precautions: Discontinue use immediately if signs or symptoms of skin reactions develop.
Immune reconstitution syndrome has been reported; monitoring recommended; further evaluation and treatment of opportunistic infections may be necessary.
Chewable tablets contain phenylalanine.
항생제
